Bookmark
Forward
QuickView for Triazolam (compound)
PubChem
| Name: | Triazolam |
|---|---|
| PubChem Compound ID: | 5556 |
| Description: | A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. |
| Molecular formula: | C17H12Cl2N4 |
| Molecular weight: | 343.21 g/mol |
| Synonyms: |
8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; nchembio747-comp15; 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(o-chlorophenyl)-1-methyl-; DEA No. 2887; Triazolam [USAN:BAN:INN:JAN]; 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-; 28911-01-5; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; EINECS 249-307-3; Triazolam.
show more » |
DrugBank
Identification
| Name: | Triazolam |
|---|---|
| Name (isomeric): | DB00897 |
| Drug Type: | small molecule |
| Description: | A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. |
| Synonyms: |
DEA No. 2887; Triazolamum [INN-Latin]
|
| Brand: | Novidorm, Clorazolam, Songar, Halcion, Novo-Triolam, Novodorm, Gen-Triazolam, Apo-Triazo, Alti-Triazolam |
| Category: | Adjuvants, Anesthesia, Benzodiazepines, Anti-anxiety Agents, GABA Modulators |
| CAS number: | 28911-01-5 |
Pharmacology
| Indication: | For the short-term treatment of insomnia. |
|---|---|
| Pharmacology: |
A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most ot...
show more » |
| Mechanism of Action: |
Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by ...
show more » |
| Absorption: | Bioavailability is 44% (oral) and 53% (sublingual). |
| Biotransformation: | Hepatic. Small amounts of unmetabolized triazolam appear in the urine. |
| Route of elimination: | Triazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion. |
| Half Life: | 1.5-5.5 hours |
| Toxicity: | Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
